A call for a consortium for optimal management of drug-drug interactions in patient care.
During clinical development of medicines, manufacturers are obliged to assess the risk of drug-drug interactions (DDIs) with their new drug. There is no doubt that product labels of drugs that are nowadays introduced to the market contain much more information on DDIs than in the past. Indeed, the drug label is often the first source for DDIs available to physicians and pharmacists. But how informative are the data presented in the drug labels?
Radboud University Medical Center & Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands.
D M
DM
Burger
Radboud University Medical Center & Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands.
E J
EJ
Smolders
National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel.
J
J
Schapiro
Radboud University Medical Center & Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands.
Jph
J
Drenth
University of Liverpool, UK.
D J
DJ
Back
D015195:Drug Design; D004347:Drug Interactions; D004348:Drug Labeling; D006801:Humans; D005791:Patient Care / Q000379:methods; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010595:Pharmacists / Q000458:organization & administration; D010820:Physicians / Q000458:organization & administration; D024382:Professional Role
D004364:Pharmaceutical Preparations